CS277525B6 - Mixture against migraine - Google Patents

Abstract

The solution relates to an antimigraine mixture for migraine headaches of all types, which contains 150 to 400 mg of paracetamol, 150 to 350 mg of acetylsalicylic acid in buffered form, 0.6 to 2.0 mg of ergotamine tartaricum, 50 to 150 mg of caffeine, 5 to 20 mg of codeine dihydrogenphosphoricum and 15 to 30 mg of phenobarbital. The solution can be used in medicine in the field of neurology.

Description

1 CS 277525 B6

The invention relates to an anti-migraine composition which also acts in a state of full developed migraine attack.

Serious world statistics of 5 to 10% of the population (mainly women aged 17 to 55) suffer from migraine headaches. Patients are treated on an outpatient basis or are hospitalized. .

In the treatment of an acute migraine condition (the patient should be hospitalized for all physicians), single-component drugs such as Cornutamine (ergotaminium tartari-cum), Dihydergot (dihydroergotamine methanesulfonate), Protazine (promethniinium chloride), Diazepam (chlordiazepoxide), Papaverine (papaverine hydrochloride) ), Indren (indomethacin); from multi-component eg Ergophein (ergotaminium tartaricum + coffeinum), Bellaspon (ergotaminium tartaricum + radobelin + phenobarbital), Spasmoveralgin (aminophenazone + brominated + phenobarbital + papaverine hydrochloride + codein dyhydrogenphosphoricum + ephedin-rinium hydrochloride + metobromide), Sedolor (phenacetin + amino-phenazone + caffeine), Migrenine (phenazum cum acid citricum).

For example, Clavigrenin (dihydroergotaminium mesylicum), Secatoxin (dihydroergotoxin), Lysenyl (lysuridium hydrogen maleate), Cornutamin, Divascol (tolazolium chloride), Sandomigran (pizotifenum) are used to prevent seizures.

A disadvantage of the preparations used in acute seizures is their poor efficacy and unreliability, leading to an increase in the dose of the adverse effects (heart, vessels, digestive tract, CNS). The preparations used to prevent long-term cures (several weeks to months) do not significantly reduce the frequency and intensity of seizures. Prolonged administration of e.g. doses (5-12 tablets once).

Despite great scientific advances, the current problem of treating migraine (similar to other vasogenic diseases) is not resolved.

By monitoring the effects of some of the hitherto used preparations as well as new medicaments, it has been possible to prepare an anti-migraine composition according to the invention which eliminates most of the disadvantages of the currently used migraine drugs. SUMMARY OF THE INVENTION The anti-migraine composition comprises 150 to 400 mg of paracetamol, 150 to 350 mg of acetylsalicylic acid in buffered form, 0.6 to 2.0 mg of ergotaminium tartaric, 50 to 150 mg of caffeine, 5 to 20 mg of codeine dihydrogenphosphoric acid 15 to 15 mg. 30 mg phenobarbitol, which by its composition is gentle, but surprisingly very effective, with the effect of such intensity as has not been described. This anti-migraine composition of the present invention, at relatively low levels of the individual drug substance, provides the desired CS 277525 B6 effects not only in the migraine state in the still underdeveloped state, but also in a fully developed seizure state, even where treatment has not been successful.

When administered in an undeveloped aura, the effect occurs 10 to 25 minutes (depending on the gastric content) and is definitive, i.e., the seizure does not develop. When administered at the stage of full-blown seizure, the effect occurs within 20 to 30 minutes in the event of incomplete elimination (depending on the seizure type), one to two hours can be given a dose that is definitely binge. The need for a third dose for definitive elimination of seizure is rare. By administering this mixture, they are even prolonged between each seizure and halved. By administering an anti-migraine blend of subfamilies only in acute conditions, e.g. 1 to 2 bouts of seizure (ie not preventive, long-term) reduce the risk of exceeding individual and daily doses, as well as the risk of adverse effects. Co-operation between the doctor and the patient is greatly improved, as many of the previously unsuccessful long-term treatments are the starting point of their condition.

These examples illustrate but do not limit the invention

Migraine mixture (1) paracetamol 250 mg acetylsalicylic acid 350 mg ergotaminium tartaric 1.5 mg caffeine 50.0 mg codein dihydrogenphosphoricum 10.0 mg phenobarbital 15.0 mg was prepared by mixing the individual ingredients into a powder.

In the same way, an anti-migraine mixture (2) was prepared by mixing paracetamol 350.0 mg acetylsalicylic acid 200.0 mg ergotaminium tartaricum 0.8 mg caffeine 150.0 mg codeinum dihydrogenphosphoric 15.0 mg phenobarbital 25.0 mg and finalizing into tablet form.

The anti-migraine compositions (1, 2) of the invention were as follows: test substance 1st patient 2nd patient 3rd patient 4th patient Sandomigran - - - - mixture (1) + - Φ +++ ++ mixture (2 ) Φ ++ Φ Φ

Claims (1)

PATENT CLAIMS An antimigraine mixture, characterized in that it contains e. 150 to 400 mg of paracetamol, 150 to 350 mg of acetylsalicylic acid in buffered form, 0.6 to 2.0 mg ergotamine tartaric acid, 50 to 150 mg of caffeine, 5 to 20 mg codeinum dihydrogenphosphoricum a 15 to 30 mg of phenobarbital.